Sichuan Huiyu Pharmaceutical Co (688553) Fair Value & Analysis
Healthcare · CN · Market cap 6.9B CNY
Fair value as of: Jul 12, 2026
From 4 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥39.92 to ¥5.00 (−87.5%) since Jun 24, 2026. Share price −22.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥9.86 – ¥27.61 · fair‑value band ¥4.78 – ¥5.22 · the ¥12.63 price screens above the ¥5.00 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sichuan Huiyu Pharmaceutical Co (688553) currently trades at ¥12.63, while our model-based Fair Value estimate is ¥5.00 — implying the stock looks roughly 60.4% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Sichuan Huiyu Pharmaceutical Co generated revenue of 1.0B CNY at a net margin of 2.2%. Revenue grew 12.6% year over year. It earns a return on equity of 0.5%. The balance sheet holds a net cash position of 1.7B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥4.78 (bear case) to ¥5.22 (bull case); at ¥12.63, the current price sits above that range. The share trades about 55% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -60%, 688553 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sichuan Huiyu Pharmaceutical Co reported revenue of ¥998M in FY2025 versus ¥1.8B in FY2021, a compound −14.0%/yr. Reported net income was −¥24.2M in FY2025.
Is 688553 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sichuan Huiyu Pharmaceutical Co (688553) undervalued?
What is the fair value of 688553?
What is the quality score of 688553?
What is the revenue of Sichuan Huiyu Pharmaceutical Co (688553)?
What is the net profit margin of 688553?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Sichuan Huiyu Pharmaceutical Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.